Two Sigma Advisers’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Two Sigma Advisers’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-111,000	Closed	-$167K	–	2758
2023 Q1	$167K	Sell	111,000 -138,653	-56%	-$187K	﹤0.01%	2302
2022 Q4	$249K	Sell	249,653 -144,947	-37%	-$195K	﹤0.01%	2124
2022 Q3	$710K	Sell	394,600 -60,100	-13%	-$174K	﹤0.01%	1697
2022 Q2	$1.32M	Sell	454,700 -258,400	-36%	-$637K	﹤0.01%	1447
2022 Q1	$1.97M	Buy	713,100 +119,700	+20%	+$377K	0.01%	1267
2021 Q4	$2.77M	Buy	593,400 +402,900	+211%	+$2.52M	0.01%	1030
2021 Q3	$1.62M	Sell	190,500 -88,100	-32%	-$1.24M	﹤0.01%	1368
2021 Q2	$4.57M	Sell	278,600 -17,400	-6%	-$351K	0.01%	906
2021 Q1	$6.54M	Buy	296,000 +232,400	+365%	+$6.34M	0.02%	745
2020 Q4	$1.97M	Buy	+63,600	New	+$1.61M	0.01%	1268

Two Sigma Advisers's TCRR Position: Q2 2023 in Review

Two Sigma Advisers sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 111,000 shares — an estimated $167K sold.

Two Sigma Advisers first reported a position in TCRR in Q4 2020 and held it in 10 quarters. The position peaked at $6.54M in Q1 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

Two Sigma Advisers reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Two Sigma Advisers sold 111,000 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $167K.
Two Sigma Advisers first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2020 and held it in 10 quarters.
Two Sigma Advisers's TCR2 Therapeutics Inc. Common Stock position peaked at $6.54M in Q1 2021.
0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Two Sigma Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.